Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Aquestive Therapeutics (AQST) reported a Q4 loss of $0.19 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is a larger loss compared to $0.12 per share a year ago.
March 05, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aquestive Therapeutics reported a larger-than-expected Q4 loss of $0.19 per share, missing the consensus estimate of $0.14 and widening from last year's $0.12 loss.
The reported loss per share of $0.19 is worse than the expected $0.14, indicating underperformance. This is likely to negatively impact the stock price in the short term as it reflects a larger loss compared to both the estimate and the previous year's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100